학술논문
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Document Type
article
Author
Maria Gonzalez-Cao; Clara Mayo de las Casas; Juana Oramas; Miguel A. Berciano-Guerrero; Luis de la Cruz; Pablo Cerezuela; Ana Arance; Eva Muñoz-Couselo; Enrique Espinosa; Teresa Puertolas; Roberto Diaz Beveridge; Sebastian Ochenduszko; Maria-Jose Villanueva; Laura Basterretxea; Lorena Bellido; Delvys Rodriguez; Begoña Campos; Clara Montagut; Ana Drozdowskyj; Miguel A. Molina; Jose Antonio Lopez-Martin; Alfonso Berrocal
Source
Nature Communications, Vol 12, Iss 1, Pp 1-6 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and cobimetinib combination as first-line treatment of patients with unresectable or metastatic advanced melanoma with BRAFV600 mutation